06/01/23 8:30 AMNasdaq : VERU managementVeru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory BoardVeru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of ErikRHEA-AIneutral
05/24/23 8:30 AMNasdaq : VERU conferencesVeru to Present at the Jefferies Healthcare ConferenceVeru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that Mitchell Steiner, M.D.,RHEA-AIneutral
05/11/23 6:30 AMNasdaq : VERU earningsVeru Reports Fiscal 2023 Second Quarter Financial ResultsAgreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS), including two planned interim efficacy analyses ENTADFI ® product sold for $20 million, plus up toRHEA-AIneutral
05/04/23 8:30 AMNasdaq : VERU clinical trialcovid-19Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDSReached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all WHO-4, WHO-5, and WHO-6 hospitalized adult COVID-19 patients at high risk for ARDS regardless of theRHEA-AIneutral
05/03/23 8:30 AMNasdaq : VERU Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park CapitalVeru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that it has entered into aRHEA-AIneutral
04/27/23 6:45 AMNasdaq : VERU conferencesearningsVeru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced it will host a conference call and audio webcast on Thursday, May 11, 2023,RHEA-AIneutral
04/20/23 6:45 AMNasdaq : VERU Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales MilestonesVeru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced the sale of its ENTADFI ® (finasteride and tadalafil) capsules business forRHEA-AIneutral
04/19/23 8:30 AMNasdaq : VERU Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health SectorVeru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases that has a commercial sexual health division, today announced it has entered into aRHEA-AIvery positive
04/11/23 8:30 AMNasdaq : VERU clinical trialVeru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits PoxvirusesSabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome (ARDS) Company plans pre-Investigational New Drug (IND) meeting with FDA to evaluateRHEA-AIneutral
04/04/23 8:30 AMNasdaq : VERU clinical trialcovid-19Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 ProgramIn the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model Positive Phase 3 COVID-19 clinical study and preclinical influenza study further support the potential use ofRHEA-AIneutral